Rena Therapeutics Overview
- Year Founded
-
2015
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
M&A
Rena Therapeutics General Information
Description
Developer of Hetero-Duplex oligonucleotides technology designed for a technology platform applicable to drug discovery research of nucleic acid medicines. The company offers Hetero-Duplex oligonucleotides technology nucleic acid medicines, the mechanism associated with a gene that is a therapeutic target is elucidated in medical research or clinical practice, the sequence information of that gene can be used to design pharmaceutical compounds, thereby enabling its clients to facilitate the development of any nucleic acid therapeutics in pipelines.
Contact Information
Website
www.renatherapeutics.com(Operating Subsidiary)
Corporate Office
- Global Business Hub Tokyo, 3rd floor, Otemachi Financial City Cube
- 1-9-2 Otemachi
- Chiyoda-ku, Tokyo 100-0004
- Japan
Corporate Office
- Global Business Hub Tokyo, 3rd floor, Otemachi Financial City Cube
- 1-9-2 Otemachi
- Chiyoda-ku, Tokyo 100-0004
- Japan
Rena Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 21-Nov-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 30-Jun-2017 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 20-Apr-2015 | $5.02M | $5.02M | Completed | Startup |
Rena Therapeutics Patents
Rena Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024089860-A | Nucleic acid complex for modulating zic5 expression | Active | 22-Dec-2022 | ||
| JP-7933315-B2 | Nucleic acid complexes for regulating zic5 expression | Active | 22-Dec-2022 | ||
| US-20260185102-A1 | Ligand-binding nucleic acid complex | Pending | 02-Nov-2021 | ||
| EP-4428238-A1 | Ligand-bound nucleic acid complex | Pending | 02-Nov-2021 | ||
| EP-4428238-A4 | Ligand-bound nucleic acid complex | Pending | 02-Nov-2021 | C07K14/635 |
Rena Therapeutics Signals
Rena Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DBJ Capital | Corporate Venture Capital | Minority | ||
| Innovation Network Corporation of Japan | Growth/Expansion | Minority | ||
| KSP (Kawasaki) | Corporation | Minority |
Rena Therapeutics FAQs
-
When was Rena Therapeutics founded?
Rena Therapeutics was founded in 2015.
-
Where is Rena Therapeutics headquartered?
Rena Therapeutics is headquartered in Chiyoda-ku, Japan.
-
What is the size of Rena Therapeutics?
Rena Therapeutics has 12 total employees.
-
What industry is Rena Therapeutics in?
Rena Therapeutics’s primary industry is Drug Discovery.
-
Is Rena Therapeutics a private or public company?
Rena Therapeutics is a Private company.
-
What is Rena Therapeutics’s current revenue?
The current revenue for Rena Therapeutics is .
-
How much funding has Rena Therapeutics raised over time?
Rena Therapeutics has raised $10.4M.
-
Who are Rena Therapeutics’s investors?
DBJ Capital, Innovation Network Corporation of Japan, and KSP (Kawasaki) have invested in Rena Therapeutics.
-
When was Rena Therapeutics acquired?
Rena Therapeutics was acquired on 21-Nov-2019.
-
Who acquired Rena Therapeutics?
Rena Therapeutics was acquired by Nippon Shokubai.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process